INDEPENDENT INTELLIGENCE
LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Atea Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERAVIR
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / AVIR COVERAGE

What’s moving Atea Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

The story matters when it changes Atea Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Call Transcript

Investors are testing whether Atea Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) insider upped their holding by 106% earlier this year

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) insider upped their holding by 106% earlier this year

The story matters when it changes Atea Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q1 2022 Results

The story matters when it changes Atea Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcript

Investors are testing whether Atea Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Here's What Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shareholder Ownership Structure Looks Like

Here's What Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shareholder Ownership Structure Looks Like

Investors are testing whether Atea Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest AVIR filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-12 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-12 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-05 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-22 · Period 2026-06-18SEC ↗8-KMaterial company eventFiled 2026-05-12 · Period 2026-05-12SEC ↗8-KMaterial company eventFiled 2026-03-05 · Period 2026-03-05SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-27 · Period 2026-06-18SEC ↗4Official SEC filingFiled 2026-06-23 · Period 2026-06-18SEC ↗
EARNINGS / QUARTERLY TRACKER

Atea Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.